<DOC>
	<DOCNO>NCT01309412</DOCNO>
	<brief_summary>The purpose study assess safety tolerability siltuximab 11.0 mg/kg combination bortezomib dexamethasone patient relapse refractory multiple myeloma .</brief_summary>
	<brief_title>A Phase 1 Study CNTO 328 ( Siltuximab ) Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>This study open-label ( physician patient know name study drug ) , multicenter ( one site ) study siltuximab patient relapse refractory multiple myeloma receive siltuximab combination bortezomib/dexamethasone evaluate safety , pharmacokinetics ( drug absorb body , distribute within body remove body time ) , efficacy immunogenicity ( ability induce immune response ) . This study plan dose escalation siltuximab level 5.5 mg/kg ( Dose Level 1 ) 11.0 mg/kg ( Dose Level 2 ) give intravenously . Recommended dos determine base incidence dose-limiting toxicity patient relapse refractory multiple myeloma siltuximab dose level 5.5 mg/kg 11.0 mg/kg administer bortezomib/dexamethasone . Treatment siltuximab start Dose Level 1 , treatment Dose Level 2 start complete safety evaluation end observation period Cycle 1 patient Dose level 1 . Once 11.0 mg/kg determine recommend dose , dose patient whose start dose 5.5 mg/kg , achieve complete response , escalate 11.0 mg/kg base patient consent investigator discretion next cycle . Siltuximab give 5.5 11.0 mg/kg intravenous infusion 1 hour Day 1 21-day cycle progression . Twice-weekly intravenous administration bortezomib 1.3 mg/m2 ( Days 1 , 4 , 8 , 11 ) follow 10-day rest period ( Days 12-21 ) . Four-per-week oral administration dexamethasone 20 mg ( Days 1 , 2 , 4 , 5 , 8 , 9 , 11 12 ) follow 9-day rest period ( Days 13-21 ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Siltuximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients proven symptomatic nonsecretory multiple myeloma Patients measurable lesion Patients previously receive 13 regimen multiple myeloma Patients must progress refractory recent line treatment Patients Eastern Cooperative Oncology Group performance status 02 Patients follow laboratory value within 14 day schedule day initial administration study drug : hemoglobin 8 g/dL , absolute neutrophil count 1,000/mm3 , platelet count 50,000/mm3 , aspartate aminotransferase , alanine aminotransferase 2.5 time upper limit normal range , total bilirubin 1.5 time upper limit normal range , calculate creatinine clearance 20 mL/min , correct serum calcium le 12.5 mg/dL Patients primary amyloidosis , plasma cell leukemia condition Mprotein present absence clonal plasma cell infiltration lytic bone lesion Patients Grade 1 peripheral neuropathy pain Grade 2 high peripheral neuropathy Patients undergone allogeneic bone marrow transplantation within 28 day start treatment study drug Patients expose agent target interleukin6 ( IL6 ) IL6 receptor Patients refractory bortezomib Patients treatment discontinue toxicity bortezomib Patients require dose reduction toxicity bortezomib Patients receive chemotherapy , plasmapheresis radiation therapy within 21 day start treatment ( within 42 day nitrosoureas ) Patients undergone major surgery include open biopsy ( exclude bone marrow ) within 21 day study treatment planning surgery ( except minor surgical procedure ) study Human immunodeficiency virus antibodypositive , hepatitis C virus antibodypositive hepatitis B surface antigenpositive patient Patients know hypersensitivity boron mannitol Patients history unmanageable severe infusion reaction monoclonal antibody murine , chimeric human proteins excipients Patients concurrent medical condition likely interfere study procedure result , opinion investigator would constitute hazard participate study Patients significant cardiac disease characterize significant ischemic coronary disease , significant arrhythmia , congestive heart failure ( New York Heart Association Class III IV ) myocardial infarction within 6 month first dose study drug Patients clinically diagnose pneumonitis ( interstitial pneumonia ) pulmonary fibrosis abnormal interstitial shadow bilaterally chest CT , without symptom</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Relapsed refractory multiple myeloma</keyword>
	<keyword>CNTO 328</keyword>
	<keyword>siltuximab</keyword>
	<keyword>bortezomib</keyword>
	<keyword>dexamethasone</keyword>
</DOC>